ES2096343T3 - Oligonucleotido terapeutico anti-hiv y composicion farmaceutica. - Google Patents

Oligonucleotido terapeutico anti-hiv y composicion farmaceutica.

Info

Publication number
ES2096343T3
ES2096343T3 ES93924289T ES93924289T ES2096343T3 ES 2096343 T3 ES2096343 T3 ES 2096343T3 ES 93924289 T ES93924289 T ES 93924289T ES 93924289 T ES93924289 T ES 93924289T ES 2096343 T3 ES2096343 T3 ES 2096343T3
Authority
ES
Spain
Prior art keywords
hiv
pharmaceutical composition
oligonucleotides
therapeutic oligonucleotide
hiv therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93924289T
Other languages
English (en)
Inventor
Sudhir Agrawal
Jin Yan Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of ES2096343T3 publication Critical patent/ES2096343T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE PRESENTAN OLIGONUCLEOTIDOS QUE TIENEN SECUENCIAS DE NUCLEOTIDOS QUE SE HIBRIDAN AL MENOS LOS NUCLEOTIDOS DEL 324 AL 348 DE UNA REGION GAG CONSERVADA DEL GENOMA DEL VIH-1. ESTOS OLIGONUCLEOTIDOS TIENEN ALREDEDOR DE 25 A 30 NUCLEOTIDOS ENLAZADOS MEDIANTE AL MENOS UN ENLACE INTERNUCLEOTIDO NO FOSFODIESTER QUE LOS HACE RESISTENTES A LA DIGESTION DE NUCLEASA. TAMBIEN SE PRESENTAN FORMULACIONES TERAPEUTICAS QUE CONTIENEN TALES OLIGONUCLEOTIDOS Y LOS METODO PARA INHIBIR LA PROLIFERACION DEL VIH-1 Y PARA EL TRATAMIENTO DE UN MAMIFERO CON INFECCIONES PROVOCADAS POR EL VIH-1.
ES93924289T 1992-10-05 1993-10-04 Oligonucleotido terapeutico anti-hiv y composicion farmaceutica. Expired - Lifetime ES2096343T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95813592A 1992-10-05 1992-10-05

Publications (1)

Publication Number Publication Date
ES2096343T3 true ES2096343T3 (es) 1997-03-01

Family

ID=25500631

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93924289T Expired - Lifetime ES2096343T3 (es) 1992-10-05 1993-10-04 Oligonucleotido terapeutico anti-hiv y composicion farmaceutica.

Country Status (19)

Country Link
US (1) US5684147A (es)
EP (1) EP0664833B1 (es)
JP (1) JPH08504570A (es)
KR (1) KR950704482A (es)
AT (1) ATE146819T1 (es)
AU (1) AU678415B2 (es)
BR (1) BR9307191A (es)
CA (1) CA2146364A1 (es)
CZ (1) CZ85495A3 (es)
DE (1) DE69306969T2 (es)
DK (1) DK0664833T3 (es)
ES (1) ES2096343T3 (es)
FI (1) FI951600L (es)
GR (1) GR3022315T3 (es)
HU (1) HUT72400A (es)
NO (1) NO951307L (es)
NZ (1) NZ257434A (es)
PL (1) PL308261A1 (es)
WO (1) WO1994008004A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US5733781A (en) * 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
RU2136752C1 (ru) * 1997-05-22 1999-09-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Способ ингибирования репродукции вируса иммунодефицита человека
EP1584681A3 (en) * 1997-07-10 2005-11-09 GeneSense Technologies Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
ES2255732T3 (es) 1997-08-19 2006-07-01 Idera Pharmaceuticals, Inc. Oligonucleotidos especificos de vih y procedimientos para su utilizacion.
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
NZ512244A (en) 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
JP4824236B2 (ja) * 1999-07-09 2011-11-30 ジェン−プローブ・インコーポレーテッド 核酸増幅によるｈｉｖ−１の検出
WO2001046448A1 (en) * 1999-12-23 2001-06-28 The Board Of Regents Of The University Of Texas System Inhibition of cellular proteases
AU2001227889A1 (en) * 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP2002125687A (ja) * 2000-10-30 2002-05-08 Tosoh Corp Ｈｉｖ−１検出のためのオリゴヌクレオチドおよび検出法
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
ATE411054T1 (de) 2001-08-17 2008-10-15 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1647595A1 (en) * 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
US8399423B2 (en) * 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
ATE512228T1 (de) 2005-11-17 2011-06-15 Tet Systems Gmbh & Co Kg Induzierbare expressionssysteme
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
NZ592159A (en) 2005-12-09 2012-12-21 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
US9273118B2 (en) 2009-07-15 2016-03-01 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
CN103429615B (zh) 2010-12-02 2018-03-16 埃姆医疗有限公司 用于生产高亲和力抗体的方式和方法
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
CA2958402C (en) * 2013-08-26 2021-02-02 The Royal Institution For The Advancement Of Learning / Mcgill University Antisense-based small rna agents targeting the gag open reading frame of hiv-1 rna
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CA2938193C (en) 2014-01-31 2023-05-02 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331939B1 (en) * 1988-02-16 2001-11-14 Greatbatch Gen-Aid, Ltd Modified cells having resistance to retroviral infection
JPH04501052A (ja) * 1988-02-26 1992-02-27 ザ・ウスター・フアウンデーシヨン・フオー・バイオメデイカル・リサーチ 外来性オリゴヌクレオチドによるｈｔｌｖ―３の抑制

Also Published As

Publication number Publication date
AU678415B2 (en) 1997-05-29
HU9500995D0 (en) 1995-06-28
EP0664833B1 (en) 1996-12-27
KR950704482A (ko) 1995-11-20
CA2146364A1 (en) 1994-04-14
FI951600A0 (fi) 1995-04-04
US5684147A (en) 1997-11-04
FI951600A7 (fi) 1995-05-10
BR9307191A (pt) 1999-03-30
WO1994008004A1 (en) 1994-04-14
NO951307L (no) 1995-06-01
EP0664833A1 (en) 1995-08-02
DE69306969T2 (de) 1997-05-07
NO951307D0 (no) 1995-04-04
GR3022315T3 (en) 1997-04-30
NZ257434A (en) 1997-01-29
AU5402894A (en) 1994-04-26
DK0664833T3 (da) 1997-04-14
JPH08504570A (ja) 1996-05-21
ATE146819T1 (de) 1997-01-15
CZ85495A3 (en) 1996-03-13
HUT72400A (en) 1996-04-29
DE69306969D1 (de) 1997-02-06
FI951600L (fi) 1995-05-10
PL308261A1 (en) 1995-07-24

Similar Documents

Publication Publication Date Title
ES2096343T3 (es) Oligonucleotido terapeutico anti-hiv y composicion farmaceutica.
DK168061B1 (da) Med mrna hybridiserbart anti-viralt middel
US6372427B1 (en) Cooperative oligonucleotides
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
UY25869A1 (es) Moduladores de ccr5, formulaciones farmacéuticas, procedimientos y sus usos.
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
RU2005133711A (ru) Антисмысловые олигонуклеотиды (odn) к smad7 и их применение в области медицины
WO1994024144A3 (en) Enhanced triple-helix and double-helix formation with oligomers containing modified purines
ES2125251T3 (es) Inhibidores de la proteasa del vih.
ES2179451T3 (es) Compuestos de 2-alquiliden-19-nor-vitamina d.
PT100472A (pt) Sequencias genomicas do virus da hepatite c e composicoes farmaceuticas que as contem, para diagnostico e terapeutica da hepatite c
ES2120036T3 (es) Virus recombinantes y su utilizacion en terapia genetica.
Stein et al. Phosphorothioate oligodeoxynucleotide analogues
PT1175489E (pt) Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas
KR960704034A (ko) 단백질 생산, 세포 증식 및(또는) 전염병 병원균의 증식에 대한 올리고뉴클레오티드 저해의 향상법(Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and/or Multiplication of Infectious Disease Pathogens)
ES2166748T3 (es) Represor multivalente de la funcion genica.
MX9703188A (es) Acidos nucleicos de aminoacido.
KR960000914A (ko) 이소프레닐 단백질 트랜스퍼라아제의 발현을 억제하는 올리고뉴클레오티드
BR9910095A (pt) Compostos inibidores de spla2 para tratamento de doença
BARTON et al. TREATMENT OF EARLY SYPHILIS WITH PENICILLIN: Report on Three Hundred and Twenty-Four Patients Treated with 1,200,000 Units Over Seven and One-Half Days
NO945020L (no) Selv-stabiliserende oligonukleotider som terapeutiske midler
AR073665A1 (es) Dsarn para el tratamiento de infeccion de virus de arn de cadenas positivas, tales como el virus de hepatitis c (hcv)
ES2081782T1 (es) Extractos procedentes de piliostigma thonningil, usos de estos y formulaciones que los contienen.
DK0611373T3 (da) Oligo-2-desoxynukleotider og deres anvendelse som lægemidler med antiviral virkning.
JPH0834738A (ja) 新規抗ｈｉｖ剤

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 664833

Country of ref document: ES